Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis
NCT ID: NCT07131969
Last Updated: 2025-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2025-09-30
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Challenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited.
Aim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant.
Importance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery
NCT01435421
Biomarkers in Liver Failure
NCT02833064
Causes, Complications and Outcomes of Severe Acute Liver Disease Cases Admitted to Intensive Care Units
NCT05879445
Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"
NCT01201720
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure
NCT01582087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with acute liver failure or sepsis
blood draw
Venous blood sampling into Tempus tube for RNA-sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood draw
Venous blood sampling into Tempus tube for RNA-sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* all cause sepsis admitted to ICU
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Society of Intensive Care Medicine
OTHER
University of Cambridge
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dhupal Patel
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Birmingham
Birmingham, , United Kingdom
Addenbrooke's Hospital
Cambridge, , United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, , United Kingdom
Leeds General Infirmary
Leeds, , United Kingdom
Kings College Hospital
London, , United Kingdom
Royal Free Hospital
London, , United Kingdom
Freeman Hospital
Newcastle, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Andrew Conway-Morris
Role: primary
Andrew Ratcliffe
Role: primary
Mark McPhail
Role: primary
Amy Sangam
Role: primary
Iain McCullagh
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A097365
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.